There is provided a protein stabilizer containing a compound represented by Formula (1) as an active ingredient. The protein stabilizer is capable of stabilizing a protein in a solution state for a long period of time without affecting an assay system, the protein being not limited to enzymes, labeling substances such as fluorescent substances and chemiluminescent substances, and assay target substances. There is also provided a protein stabilization method containing making the protein coexist with the compound represented by Formula (1) in a water-containing solution.

##STR00001##

In Formula (1), X is a hydrogen atom or a methyl group, and n is an integer of 3 to 17.

There is provided a protein stabilizer containing a compound represented by Formula (1) as an active ingredient. The protein stabilizer is capable of stabilizing a protein in a solution state for a long period of time without affecting an assay system, the protein being not limited to enzymes, labeling substances such as fluorescent substances and chemiluminescent substances, and assay target substances. There is also provided a protein stabilization method containing making the protein coexist with the compound represented by Formula (1) in a water-containing solution.

##STR00001##

In Formula (1), X is a hydrogen atom or a methyl group, and n is an integer of 3 to 17.

A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.

The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)-active and toll-like receptor (TLR8)-active imidazoquinolines and oxoadenines.

The present invention relates to a process for phospholipidation of imidazoquinolines and oxoadenines. More particularly, the present invention relates to a high-yielding and scalable procedure for the phospholipidation of imidazoquinolines and oxoadenines which obviates the need to isolate unstable phosphoramidite intermediates. This process may be used for the phospholipidation of toll-like receptor 7 (TLR7)-active and toll-like receptor (TLR8)-active imidazoquinolines and oxoadenines.

Cells incorporating a synthetic molecule construct of the structure F—S.sub.1—S.sub.2-L where: F—S.sub.1 is an aminoalkylglycoside where F is a mono-, di-, tri- or oligo-saccharide and S.sub.1 is 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, or 5-aminopentyl; S.sub.2 is —CO(CH.sub.2).sub.2CO—, —CO(CH.sub.2).sub.3CO—, —CO(CH.sub.2).sub.4CO— or —CO(CH.sub.2).sub.5CO—; and L is phosphatidylethanolamine.

Cells incorporating a synthetic molecule construct of the structure F—S.sub.1—S.sub.2-L where: F—S.sub.1 is an aminoalkylglycoside where F is a mono-, di-, tri- or oligo-saccharide and S.sub.1 is 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, or 5-aminopentyl; S.sub.2 is —CO(CH.sub.2).sub.2CO—, —CO(CH.sub.2).sub.3CO—, —CO(CH.sub.2).sub.4CO— or —CO(CH.sub.2).sub.5CO—; and L is phosphatidylethanolamine.

The invention relates to a method for aggregating and separating an organic material mixture which is provided in a dissolved form in an aqueous emulsion. The method is characterized by the following steps: a) providing an aqueous emulsion with organic compounds which are provided in the emulsion in a dissolved form, said organic compounds being carboxylic acids, phospholipids, glycolipids, glyceroglycolipids, phenols, sterols, chlorophyll, and/or sinapines, b) mixing the emulsion from step a) with an aqueous solution containing copper(II) ions and/or calcium ions until an aggregate formation is achieved, and c) separating the aggregates from step b) by means of a sedimentation, filtration, or centrifugation process after achieving an aggregated phase of the organic compounds from step b).

A protein adsorption inhibitor includes a compound of Formula (1) as an active ingredient. The protein adsorption inhibitor is capable of highly inhibiting non-specific adsorption of a protein such as an antibody or an enzyme to a surface of a base body such as an immune reaction vessel or an assay instrument. Also provided is a coating layer-formed base body having a coating layer containing the protein adsorption inhibitor on the base body. The coating layer-formed base body has an excellent protein adsorption-inhibiting function. A method for inhibiting the adsorption of the protein to the base body is provided. The method includes forming the coating layer containing the protein adsorption inhibitor on the surface of the base body:

##STR00001##

wherein, X is a hydrogen atom or a methyl group and n is an integer of 9 to 15.

A protein adsorption inhibitor includes a compound of Formula (1) as an active ingredient. The protein adsorption inhibitor is capable of highly inhibiting non-specific adsorption of a protein such as an antibody or an enzyme to a surface of a base body such as an immune reaction vessel or an assay instrument. Also provided is a coating layer-formed base body having a coating layer containing the protein adsorption inhibitor on the base body. The coating layer-formed base body has an excellent protein adsorption-inhibiting function. A method for inhibiting the adsorption of the protein to the base body is provided. The method includes forming the coating layer containing the protein adsorption inhibitor on the surface of the base body:

##STR00001##

wherein, X is a hydrogen atom or a methyl group and n is an integer of 9 to 15.